List of Tables
Table 1. Global Viral Vector-Based Gene Therapy Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Adenovirus (AdV)
Table 3. Key Players of Adeno-associated Virus (AAV)
Table 4. Global Viral Vector-Based Gene Therapy Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 5. Global Viral Vector-Based Gene Therapy Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 6. Global Viral Vector-Based Gene Therapy Market Size by Region (2020-2025) & (US$ Million)
Table 7. Global Viral Vector-Based Gene Therapy Market Share by Region (2020-2025)
Table 8. Global Viral Vector-Based Gene Therapy Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 9. Global Viral Vector-Based Gene Therapy Market Share by Region (2026-2031)
Table 10. Viral Vector-Based Gene Therapy Market Trends
Table 11. Viral Vector-Based Gene Therapy Market Drivers
Table 12. Viral Vector-Based Gene Therapy Market Challenges
Table 13. Viral Vector-Based Gene Therapy Market Restraints
Table 14. Global Viral Vector-Based Gene Therapy Revenue by Players (2020-2025) & (US$ Million)
Table 15. Global Viral Vector-Based Gene Therapy Market Share by Players (2020-2025)
Table 16. Global Top Viral Vector-Based Gene Therapy Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Viral Vector-Based Gene Therapy as of 2024)
Table 17. Ranking of Global Top Viral Vector-Based Gene Therapy Companies by Revenue (US$ Million) in 2024
Table 18. Global 5 Largest Players Market Share by Viral Vector-Based Gene Therapy Revenue (CR5 and HHI) & (2020-2025)
Table 19. Global Key Players of Viral Vector-Based Gene Therapy, Headquarters and Area Served
Table 20. Global Key Players of Viral Vector-Based Gene Therapy, Product and Application
Table 21. Global Key Players of Viral Vector-Based Gene Therapy, Date of Enter into This Industry
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Viral Vector-Based Gene Therapy Market Size by Type (2020-2025) & (US$ Million)
Table 24. Global Viral Vector-Based Gene Therapy Revenue Market Share by Type (2020-2025)
Table 25. Global Viral Vector-Based Gene Therapy Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 26. Global Viral Vector-Based Gene Therapy Revenue Market Share by Type (2026-2031)
Table 27. Global Viral Vector-Based Gene Therapy Market Size by Application (2020-2025) & (US$ Million)
Table 28. Global Viral Vector-Based Gene Therapy Revenue Market Share by Application (2020-2025)
Table 29. Global Viral Vector-Based Gene Therapy Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 30. Global Viral Vector-Based Gene Therapy Revenue Market Share by Application (2026-2031)
Table 31. North America Viral Vector-Based Gene Therapy Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 32. North America Viral Vector-Based Gene Therapy Market Size by Country (2020-2025) & (US$ Million)
Table 33. North America Viral Vector-Based Gene Therapy Market Size by Country (2026-2031) & (US$ Million)
Table 34. Europe Viral Vector-Based Gene Therapy Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 35. Europe Viral Vector-Based Gene Therapy Market Size by Country (2020-2025) & (US$ Million)
Table 36. Europe Viral Vector-Based Gene Therapy Market Size by Country (2026-2031) & (US$ Million)
Table 37. Asia-Pacific Viral Vector-Based Gene Therapy Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 38. Asia-Pacific Viral Vector-Based Gene Therapy Market Size by Region (2020-2025) & (US$ Million)
Table 39. Asia-Pacific Viral Vector-Based Gene Therapy Market Size by Region (2026-2031) & (US$ Million)
Table 40. Latin America Viral Vector-Based Gene Therapy Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 41. Latin America Viral Vector-Based Gene Therapy Market Size by Country (2020-2025) & (US$ Million)
Table 42. Latin America Viral Vector-Based Gene Therapy Market Size by Country (2026-2031) & (US$ Million)
Table 43. Middle East & Africa Viral Vector-Based Gene Therapy Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 44. Middle East & Africa Viral Vector-Based Gene Therapy Market Size by Country (2020-2025) & (US$ Million)
Table 45. Middle East & Africa Viral Vector-Based Gene Therapy Market Size by Country (2026-2031) & (US$ Million)
Table 46. Sibiono Company Details
Table 47. Sibiono Business Overview
Table 48. Sibiono Viral Vector-Based Gene Therapy Product
Table 49. Sibiono Revenue in Viral Vector-Based Gene Therapy Business (2020-2025) & (US$ Million)
Table 50. Sibiono Recent Development
Table 51. Rigvir Group Company Details
Table 52. Rigvir Group Business Overview
Table 53. Rigvir Group Viral Vector-Based Gene Therapy Product
Table 54. Rigvir Group Revenue in Viral Vector-Based Gene Therapy Business (2020-2025) & (US$ Million)
Table 55. Rigvir Group Recent Development
Table 56. Shanghai Pharma (Sunway) Company Details
Table 57. Shanghai Pharma (Sunway) Business Overview
Table 58. Shanghai Pharma (Sunway) Viral Vector-Based Gene Therapy Product
Table 59. Shanghai Pharma (Sunway) Revenue in Viral Vector-Based Gene Therapy Business (2020-2025) & (US$ Million)
Table 60. Shanghai Pharma (Sunway) Recent Development
Table 61. Amgen Company Details
Table 62. Amgen Business Overview
Table 63. Amgen Viral Vector-Based Gene Therapy Product
Table 64. Amgen Revenue in Viral Vector-Based Gene Therapy Business (2020-2025) & (US$ Million)
Table 65. Amgen Recent Development
Table 66. Spark Therapeutics Company Details
Table 67. Spark Therapeutics Business Overview
Table 68. Spark Therapeutics Viral Vector-Based Gene Therapy Product
Table 69. Spark Therapeutics Revenue in Viral Vector-Based Gene Therapy Business (2020-2025) & (US$ Million)
Table 70. Spark Therapeutics Recent Development
Table 71. Novartis Gene Therapies Company Details
Table 72. Novartis Gene Therapies Business Overview
Table 73. Novartis Gene Therapies Viral Vector-Based Gene Therapy Product
Table 74. Novartis Gene Therapies Revenue in Viral Vector-Based Gene Therapy Business (2020-2025) & (US$ Million)
Table 75. Novartis Gene Therapies Recent Development
Table 76. Daiichi Sankyo Company Details
Table 77. Daiichi Sankyo Business Overview
Table 78. Daiichi Sankyo Viral Vector-Based Gene Therapy Product
Table 79. Daiichi Sankyo Revenue in Viral Vector-Based Gene Therapy Business (2020-2025) & (US$ Million)
Table 80. Daiichi Sankyo Recent Development
Table 81. PTC Therapeutics Company Details
Table 82. PTC Therapeutics Business Overview
Table 83. PTC Therapeutics Viral Vector-Based Gene Therapy Product
Table 84. PTC Therapeutics Revenue in Viral Vector-Based Gene Therapy Business (2020-2025) & (US$ Million)
Table 85. PTC Therapeutics Recent Development
Table 86. Research Programs/Design for This Report
Table 87. Key Data Information from Secondary Sources
Table 88. Key Data Information from Primary Sources
Table 89. Authors List of This Report
List of Figures
Figure 1. Viral Vector-Based Gene Therapy Picture
Figure 2. Global Viral Vector-Based Gene Therapy Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Viral Vector-Based Gene Therapy Market Share by Type: 2024 VS 2031
Figure 4. Adenovirus (AdV) Features
Figure 5. Adeno-associated Virus (AAV) Features
Figure 6. Global Viral Vector-Based Gene Therapy Market Size by Application (2020-2031) & (US$ Million)
Figure 7. Global Viral Vector-Based Gene Therapy Market Share by Application: 2024 VS 2031
Figure 8. Hospital Case Studies
Figure 9. Clinic Case Studies
Figure 10. Others Case Studies
Figure 11. Viral Vector-Based Gene Therapy Report Years Considered
Figure 12. Global Viral Vector-Based Gene Therapy Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 13. Global Viral Vector-Based Gene Therapy Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 14. Global Viral Vector-Based Gene Therapy Market Share by Region: 2024 VS 2031
Figure 15. Global Viral Vector-Based Gene Therapy Market Share by Players in 2024
Figure 16. Global Top Viral Vector-Based Gene Therapy Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Viral Vector-Based Gene Therapy as of 2024)
Figure 17. The Top 10 and 5 Players Market Share by Viral Vector-Based Gene Therapy Revenue in 2024
Figure 18. North America Viral Vector-Based Gene Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 19. North America Viral Vector-Based Gene Therapy Market Share by Country (2020-2031)
Figure 20. United States Viral Vector-Based Gene Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 21. Canada Viral Vector-Based Gene Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 22. Europe Viral Vector-Based Gene Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 23. Europe Viral Vector-Based Gene Therapy Market Share by Country (2020-2031)
Figure 24. Germany Viral Vector-Based Gene Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 25. France Viral Vector-Based Gene Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 26. U.K. Viral Vector-Based Gene Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 27. Italy Viral Vector-Based Gene Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 28. Russia Viral Vector-Based Gene Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. Nordic Countries Viral Vector-Based Gene Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. Asia-Pacific Viral Vector-Based Gene Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. Asia-Pacific Viral Vector-Based Gene Therapy Market Share by Region (2020-2031)
Figure 32. China Viral Vector-Based Gene Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 33. Japan Viral Vector-Based Gene Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 34. South Korea Viral Vector-Based Gene Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 35. Southeast Asia Viral Vector-Based Gene Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. India Viral Vector-Based Gene Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. Australia Viral Vector-Based Gene Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. Latin America Viral Vector-Based Gene Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. Latin America Viral Vector-Based Gene Therapy Market Share by Country (2020-2031)
Figure 40. Mexico Viral Vector-Based Gene Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 41. Brazil Viral Vector-Based Gene Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 42. Middle East & Africa Viral Vector-Based Gene Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 43. Middle East & Africa Viral Vector-Based Gene Therapy Market Share by Country (2020-2031)
Figure 44. Turkey Viral Vector-Based Gene Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 45. Saudi Arabia Viral Vector-Based Gene Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 46. UAE Viral Vector-Based Gene Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 47. Sibiono Revenue Growth Rate in Viral Vector-Based Gene Therapy Business (2020-2025)
Figure 48. Rigvir Group Revenue Growth Rate in Viral Vector-Based Gene Therapy Business (2020-2025)
Figure 49. Shanghai Pharma (Sunway) Revenue Growth Rate in Viral Vector-Based Gene Therapy Business (2020-2025)
Figure 50. Amgen Revenue Growth Rate in Viral Vector-Based Gene Therapy Business (2020-2025)
Figure 51. Spark Therapeutics Revenue Growth Rate in Viral Vector-Based Gene Therapy Business (2020-2025)
Figure 52. Novartis Gene Therapies Revenue Growth Rate in Viral Vector-Based Gene Therapy Business (2020-2025)
Figure 53. Daiichi Sankyo Revenue Growth Rate in Viral Vector-Based Gene Therapy Business (2020-2025)
Figure 54. PTC Therapeutics Revenue Growth Rate in Viral Vector-Based Gene Therapy Business (2020-2025)
Figure 55. Bottom-up and Top-down Approaches for This Report
Figure 56. Data Triangulation
Figure 57. Key Executives Interviewed
